Cargando…

Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease

TNFα is an important cytokine in inflammatory bowel disease. V565 is a novel anti-TNFα domain antibody developed for oral administration in IBD patients, derived from a llama domain antibody and engineered to enhance intestinal protease resistance. V565 activity was evaluated in TNFα-TNFα receptor-b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crowe, J. Scott, Roberts, Kevin J., Carlton, Timothy M., Maggiore, Luana, Cubitt, Marion F., Clare, Simon, Harcourt, Katherine, Reckless, Jill, MacDonald, Thomas T., Ray, Keith P., Vossenkämper, Anna, West, Michael R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862986/ https://www.ncbi.nlm.nih.gov/pubmed/29563546 http://dx.doi.org/10.1038/s41598-018-23277-7

Ejemplares similares

Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease
por: Roberts, Kevin J., et al.
Publicado: (2021)

Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis Patients
por: Nurbhai, Suhail, et al.
Publicado: (2019)

Preclinical evaluation of EPHX2 inhibition as a novel treatment for inflammatory bowel disease
por: Reisdorf, William C., et al.
Publicado: (2019)

Reduced Cytokine Tumour Necrosis Factor by Pharmacological Intervention in a Preclinical Study
por: Mooranian, Armin, et al.
Publicado: (2022)

Tumour Necrosis Factor Superfamily Members in the Pathogenesis of Inflammatory Bowel Disease
por: Ślebioda, Tomasz J., et al.
Publicado: (2014)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Validity of the self-administered comorbidity questionnaire in patients with inflammatory bowel disease
por: van Linschoten, Reinier Cornelis Anthonius, et al.
Publicado: (2023)

Preclinical evaluation of topically-administered PEGylated Fab’ lung toxicity
por: Freches, Danielle, et al.
Publicado: (2019)

Always one step ahead: How pathogenic bacteria use the type III secretion system to manipulate the intestinal mucosal immune system
por: Vossenkämper, Anna, et al.
Publicado: (2011)

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
por: Andersson, Per, et al.
Publicado: (2022)

Tumour Formation in Mice by Urethane Administered With Related Carbamates
por: Pound, A. W.
Publicado: (1972)

Bowel Necrosis in the Setting of COVID-19
por: Gartland, Rajshri M., et al.
Publicado: (2020)

Small bowel necrosis after esophagectomy
por: Shao, Longlong, et al.
Publicado: (2023)

Necrosis Avidity: A Newly Discovered Feature of Hypericin and its Preclinical Applications in Necrosis Imaging
por: Jiang, Binghu, et al.
Publicado: (2013)

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine
por: Riede, O, et al.
Publicado: (2015)

The Relationship of Fever to Tumour Necrosis in the Rat
por: Allen, Ingrid V.
Publicado: (1964)

Suppression of tumour growth by orally administered osteopontin is accompanied by alterations in tumour blood vessels
por: Rittling, S R, et al.
Publicado: (2014)

Targeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee
por: Maksymowych, Walter P, et al.
Publicado: (2012)

Pharmacokinetics and Pharmacodynamics of (S)-Ketoprofen Co-Administered with Caffeine: A Preclinical Study in Arthritic Rats
por: Medina-López, Raúl, et al.
Publicado: (2018)

Effects of intragastrically-administered Tepary bean lectins on digestive and immune organs: Preclinical evaluation
por: Alatorre-Cruz, Julia María, et al.
Publicado: (2017)

Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort
por: Bluett, James, et al.
Publicado: (2015)

Carnitine and congeners as regulators of tumour necrosis factor
por: De Simone, Claudio, et al.
Publicado: (1993)

Tumour necrosis factor-α in nasal allergy
por: Hisamatsu, K., et al.
Publicado: (1995)

Postchemoembolisation syndrome – tumour necrosis or hepatocyte injury?
por: Wigmore, S J, et al.
Publicado: (2003)

Tumour necrosis factor signalling in health and disease
por: Holbrook, Jonathan, et al.
Publicado: (2019)

A self administered reliable questionnaire to assess lower bowel symptoms
por: Adelstein, Barbara-Ann, et al.
Publicado: (2008)

Tumour necrosis factor production and natural killer cell activity in peripheral blood during treatment with recombinant tumour necrosis factor.
por: MÃ¤nnel, D. N., et al.
Publicado: (1989)

Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models
por: Belgiovine, Cristina, et al.
Publicado: (2017)

MDCT of small bowel tumours
por: Sailer, Johannes, et al.
Publicado: (2007)

In vitro photosensitization of tumour cell enzymes by photofrin II administered in vivo.
por: Gibson, S. L., et al.
Publicado: (1989)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Sildenafil normalizes bowel transit in preclinical models of constipation
por: Sharman, Sarah K., et al.
Publicado: (2017)

Effects on tumour microcirculation in mice of misonidazole and tumour necrosis factor plus hyperthermia.
por: Fujimoto, S., et al.
Publicado: (1992)

Efficacy of Topically Administered Dihydroartemisinin in Treating Papillomavirus-Induced Anogenital Dysplasia in Preclinical Mouse Models
por: Gunder, Laura C., et al.
Publicado: (2022)

Ischemic Necrosis of Small Bowel Following Laparoscopic Surgery
por: Hasson, Harrith M., et al.
Publicado: (2004)

Polymorphism in the tumour necrosis factor receptor II gene is associated with circulating levels of soluble tumour necrosis factor receptors in rheumatoid arthritis
por: Glossop, John R, et al.
Publicado: (2005)

A Study of Single Nucleotide Polymorphisms of Tumour Necrosis Factor α-1031 And Tumour Necrosis Factor β+ 252 in Chronic Rhinosinusitis
por: Misron, Khairunnisak, et al.
Publicado: (2017)

How do patients with inflammatory bowel disease want their biological therapy administered?
por: Allen, Patrick B, et al.
Publicado: (2010)

Recent advances in orally administered cell-specific nanotherapeutics for inflammatory bowel disease
por: Si, Xiao-Ying, et al.
Publicado: (2016)

Tumour necrosis factor in man: clinical and biological observations.
por: Selby, P., et al.
Publicado: (1987)

Cannot write session to /tmp/vufind_sessions/sess_kc9hpnll0h2ptjc0auke1dicg6